Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16379332 | 0.76 | TMEM97 (0.50) | TMEM97KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL26005956 | 0.74 | KCNH2 (0.42) | TMEM97KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL14731813 | 0.73 | TMEM97 (0.86) | TMEM97KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL27830059 | 0.72 | TMEM97 (0.53) | TMEM97KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL265123 | 0.72 | TAAR1 (0.57) | TMEM97KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL10087559 | 0.71 | TMEM97 (0.55) | TMEM97KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL5018566 | 0.70 | HDAC1 (0.43) | TMEM97KCNH2MEN1KMT2ATAAR1 | |
| SCHEMBL833275 | 0.69 | TAAR1 (0.61) | TAAR1HDAC1HDAC8MAOB | |
| SCHEMBL23269923 | 0.69 | TMEM97 (0.53) | TMEM97KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL21175026 | 0.69 | TMEM97 (0.53) | TMEM97KCNH2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, RNASE1 | TMEM97 1718/4885KCNH2 4358/4885MEN1 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.